Biosimilars, Wednesday 28 February 2018

last published: 01/Oct/17 16:25

Biosimilars, Thursday 1 March 2018


Organiser's Welcome Remarks


Chair's Opening Remarks

Asia's Biotech Landscape:Innovation & Funding

Carolyn Ng

Venture capital funding for the biotech industry: A case study

It takes millions of dollars to transform an innovative idea to a commercially viable pharma product. Especially in developing countries where the government has other more important priorities than to invest in early stage companies, the role of the VC becomes even more crucial and necessary for success. Investigate how VC helps biotech to take flight in the competitive generics and biosimilar-focused Asia market.
John Connolly

Fostering biotech and bio-entrepreneurship in Asia: How do we build the next biotech unicorn in Southeast Asia?

Southeast Asia is extremely diverse. It is a home to near 620 million people across 11 countries, each with different languages and religions. Among the countries many are still in the developing stage where R&D is not as much a priority than providing necessity to minimise the income gap between the rich and the needy. Yet thriving biotech landscape offering innovative solutions is starting to be seen. What needs to be done to help these promising companies to fully realise their potential? How can ASEAN come together in supporting the biotech industry in the region, as well as building the next possible biotech unicorn in SEA?
Panel discussion

The Macro View: What will it take for Asia’s biotech industry to really flourish?

Everyone knows it is too generic to classify all Asian countries in a single category. With the exception of China and India, the remaining part of Asia is complicated, fragmented and diversified. With growing GDPs and middle class populations, the potential of Asia’s biotech industry is undeniable in the eye of global leaders. The main question is, how can government and related stakeholders assist the biotech industry to flourish to provide more affordable, personalised medicine for its populations? How do countries move away from a “me-too” to “me-first” mentality, especially when it comes to pharma R&D?

Speed Networking


Exhibition Visit & Networking Refreshments

Biosimilars in Asia


Chair's Opening Remarks


Preparing for the blockbuster patent cliff 2020

Following patent cliffs for Erbitux, Rituxan, Sandostatin, Vytorin and several big blockbusters, Herceptin, Avastin are now among the next biosimilar targets. This is creating huge potential for biosimilars, prompting innovators to shift their focus to target more emerging markets which remain untapped for many companies. What trends can we expect in 2018 and beyond?
Forrest Hu

Invention vs innovation: How Asian pharma companies remain competitive in the biosimilar space

Asian companies have seen more success in the generics and biosimilars space compared to their peers in developed markets. With the success of Celltrion, Samsung, Dr Reddy’s, Biocon and more Asian pharma companies, should Asian companies focus on core expertise to improvise originator drugs, or on inventing new drugs for Asia-specific diseases?
Forrest Hu, General Manager of International Business, 3SBio Inc
Kaustubh Berde

Cost vs quality: What’s the best strategies for Asia biosimilars market?

  • Exploring strategies in addressing differences in biosimilar regulation
  • Case study: Regulated vs unregulated biosimilars market in Asia
  • Overcoming challenges in tech know-how and different approaches and understanding of concepts by regulatory agencies
Kaustubh Berde, Vice President for International Business : Emerging Markets, Wockhardt Limited

Roundtable Discussion Session

Now's your chance to get really interactive. Simply pick a table and join the debate. 

Table 10: What can we do to reconcile our diversified pharma regulations in Asia?

Table 11: Bringing it together: Roles of Patient, Pharma, Hospital and Government in Drug Development

Malini Raj, Chair, Australian Pituitary Foundation

Table 1: Upcoming vaccines in Asia and how to prepare for it

Table 2: Sustainable vaccines strategies in global health, high-income and private sector

Table 3: Sustainable biosimilar models in Asia

Table 4: Key strategies to overcome challenges in biosimilar development and manufacturing processes

Table 5: What can we learn fromCAR-T, PDL1, Cancer Vaccines successes, and what’s next in Asia?

Table 6: CRISPR & Precision medicine

Table 7: AI& Big data in drug discovery

Table 8: IoT and blockchain in clinical studies

Table 9: Pricing & Reimbursement strategies in Asia


Exhibition Visit & Networking Lunch

Biosimilar Regulation


Chair's Opening Remarks

Sandhya Kumaraswamy

Operating in countries with developing biosimilar guidelines

  • Displaying product’s similarity in clinical performance, quality, and potency
  • Convincing authorities that the designed manufacturing process is well understood and robust
  • Marketing products at a lower price as compared to originator 

Could adoption of biosimilars be slowed due to government rebates on biologics?

Biosimilars may be priced lower but government pre-existence rebates on originator products may possibly slow down uptake. If that’s the case, should companies expand to untapped emerging economies instead of focusing on developed countries?

Regulatory and quality requirements for biosimilar filing- An overview

We know South Korea, China and India are big players in biosimilars, but what about South East Asia? With over 5% GDP growth per year, countries such as Vietnam, Cambodia, Indonesia, and Malaysia have an increasingly high demand for affordable treatments. This presentation investigates the regulatory aspects in filling for approval in to access the SEA pharma industry.

Exhibition Visit & Networking Refreshments

Biosimilars Development


Choosing the right Asian country for your biosimilar trials

  • Exploring solutions for overcoming the unique challenges in running clinical trials for biosimilars in Asia
  • Overcoming knowledge gaps among investigators when it comes to handling biosimilars
  • Crafting education and awareness campaigns to promote trial participation interest
Dinesh Kundu

India’s Biosimilar clinical trials landscape: What do you need to know?

Regulation was previously a big issue in India but the country is making a comeback as a biosimilars trial destination. Join this session to learn more about the latest regulations and key requirements for conducting biosimilar trials in India. Topics include quality compliance in running biosimilar trials in India.
Dinesh Kundu, GM, Business strategy & development, Intas Pharmaceuticals Ltd. – Biopharma Division

Biocomparability and stability studies in biosimilar production

  • Key characterisation techniques to ensure biosimilar functionality
  • Discussing strategies to maintain product quality in upscaling biosimilars
  • Exploring key assays techniques and development for biosimilars testing

Networking Cocktail & Phar-East Industry Awards Presentation

last published: 01/Oct/17 16:25